Moderna lowers top end of revenue guidance as vaccine group targets cost cuts

Published 01/08/2025, 12:18
Updated 01/08/2025, 12:28
© Reuters

Investing.com - Moderna has lowered the top end of its full-year revenue forecast, citing a delay in the timing of deliveries of its COVID-19 jab to the United Kingdom (TADAWUL:4280), presenting a fresh setback for a company already aiming to slash expenses and boost recently tepid demand.

The vaccine maker said it now anticipates that annual revenue will come in at $1.5 billion to $2.2 billion, compared to a prior estimate of $1.5 billion to $2.5 billion, flagging the impact of change in the expected date of the shipments to the first quarter of its next fiscal year from the second half of 2025. Bloomberg consensus estimates had called for guidance of $2.07 billion.

Shares of Moderna (NASDAQ:MRNA) sank in premarket U.S. trading. The stock has slumped by more than 29% so far this year.

Friday’s announcement comes after Moderna announced a sweeping headcount reduction earlier this week that will see it slash around 10% of its global staff and have less than 5,000 employees by the end of the year. Moderna has been pushing to bring down costs as it grapples with flagging sales of its once mega-popular COVID-19 vaccines.

Such cost-cutting efforts helped to bring overall operating expenses for the second quarter down by 35% versus a year ago to $1.05 billion. Bancel said Moderna now expects full-year operating expenses to be between $5.9 billion to $6.1 billion, an improvement of approximately $400 million from its prior outlook.

Quarterly revenue, meanwhile, dropped by 41% to $142 million, but topped expectations for $108.5 million. Moderna’s loss per share of $2.13 for the period was also less than analysts had anticipated.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.